The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

The EU has delivered some good news to AstraZeneca's oncology business, approving its oral selective oestrogen receptor degrader (SERD) for breast cancer, even as it faces obstacles on its path to ...

GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments, including GLP-1 agonist therapies. The shift from a ...

AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic ...

Rumours earlier this week of an imminent takeover offer for Day One Biopharmaceuticals proved well-founded, but missed the mark on the identity of the acquirer. France's Servier has emerged as the ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...